XNYS
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.63 | -0.58 | +7.94% | $0 | ✅ Beat | -0.68% | +2.17% | — |
| 2026-05-12 | Q1 2026 | -0.79 | -1.32 | -67.09% | $0 | ❌ Miss | +1.72% | -3.69% | -9.14% |
| 2026-03-30 |
| Q4 2025 |
| -0.66 |
| -0.62 |
| +6.06% |
| $0 |
| ✅ Beat |
| -1.04% |
| +4.88% |
| +75.10% |
Showing last 3 quarters.